Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-07-15

Clinical Trial Update: Dasatinib in Advanced Squamous Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of dasatinib in advanced squamous cell carcinoma of the lung was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sprycel (dasatinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Squamous Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-07-15